Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy

Fig. 4

Median CRP levels by time period, categorized by HAQ-DI status at month 12. Plots show the median CRP levels for a patients who achieved normalized HAQ-DI (< 0.5) at month 12, b patients who did not achieve normalized HAQ-DI (≥ 0.5) at month 12, c patients who achieved HAQ-DI MCID (decrease from baseline of ≥ 0.22) at month 12, and d patients who did not achieve HAQ-DI MCID (increase, or decrease < 0.22 from baseline) at month 12. Error bars represent the interquartile range (Q1–Q3). ADA, adalimumab; CRP, C-reactive protein; HAQ-DI, Health Assessment Questionnaire-Disability Index; MCID, minimum clinically important difference; MTX, methotrexate; Q1, 25th percentile; Q3, 75th percentile

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us